CD5 and graft versus host disease: Zhang et al. established a strategy by anchoring CD7 in the ER and/or Golgi to overcome CAR-T cell fratricide.41 Several clinical trials have shown promising results with “off-the-shelf” CAR-T cells targeting CD7 obtained by knocking out TRAC and CD7 through CRISPR/Cas9 gene editing technology to avoid graft-versus-host disease and fratricide.25,26 In clinical trials of CAR-T therapies targeting CD5 or CD7, complete T-cell dysplasia has not been observed.